Most Read Articles
15 Jun 2017
Telomeres appear to be shorter in patients with gout than in healthy individuals, indicating increased cellular senescence, according to a study. In gout, telomere shortening is associated with flare frequency and cardiovascular (CV) disease.
16 Apr 2014

The skeleton is one of the most common sites of metastases. Metastatic tumors are the most common malignancy of bone, affecting 10 to 30 percent of cancer patients.

30 Mar 2017
Patients diagnosed with asthma are at a greater risk of schizophrenia, a new study shows. On the other hand, corticosteroid use is not tied to increased risks of schizophrenia.
Naomi Adam, 01 Feb 2014

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, the underlying cause of which is not fully known. Recently, biologic disease-modifying anti-rheumatic drugs (DMARDs) have started to be considered for the treatment of SLE due to their improved tolerability profiles compared with conventional therapies. This report profiles belimumab, a novel biologic DMARD, which has been approved for use in the treatment of certain patients with SLE.

Patient-reported outcomes hardly predict RA change in disease activity

06 Sep 2017

It appears that patient-reported pain, stiffness and fatigue at baseline offer limited value for the prediction of changes in disease activity and activity limitation in early rheumatoid arthritis (RA), according to a recent study.

Researchers recruited cases (n=1,415) to the Yorkshire Earl Arthritis Register between 1997 and 2009 to evaluate patient-reported variables as predictors of change in disease activity and disability in RA. Multilevel models were used to identify Predictors of the 28-joint Disease Activity Score (DAS28) and the Health Assessment Questionnaire-Disability Index (HAQ-DI) at baseline and change over 12 months.

The baseline predictors were the following: age, sex, symptom duration, autoantibody status, pain and fatigue visual analogue scales (VAS), DAS28, HAQ-DI, and duration of early morning stiffness (EMS).

Women had slower rates of change than men: DAS28 dropped by 0.19 and 0.17 units/month, and HAQ-DI by 0.028 and 0.023 units/month in men and women, respectively. The effects of baseline pain and EMS on rates of change were small, while fatigue VAS was only associated with DAS28 and HAQ-DI at baseline.

In patients recruited up to 2002, those with greater pain at baseline reduced DAS28 more quickly (by 0.01 unites/month of DAS28 per cm pain VAS; p=0.024). In patients recruited after 2002, there was a stronger effect for pain (by 0.01 units/month; 0.087).

Reduction in DAS28 was greater with longer EMS. In both cohorts, patients with longer EMS duration had greater reduction in HAQ-DI (p=0.006). However, pain and fatigue were not significant predictors of change in HAQ-DI, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
15 Jun 2017
Telomeres appear to be shorter in patients with gout than in healthy individuals, indicating increased cellular senescence, according to a study. In gout, telomere shortening is associated with flare frequency and cardiovascular (CV) disease.
16 Apr 2014

The skeleton is one of the most common sites of metastases. Metastatic tumors are the most common malignancy of bone, affecting 10 to 30 percent of cancer patients.

30 Mar 2017
Patients diagnosed with asthma are at a greater risk of schizophrenia, a new study shows. On the other hand, corticosteroid use is not tied to increased risks of schizophrenia.
Naomi Adam, 01 Feb 2014

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, the underlying cause of which is not fully known. Recently, biologic disease-modifying anti-rheumatic drugs (DMARDs) have started to be considered for the treatment of SLE due to their improved tolerability profiles compared with conventional therapies. This report profiles belimumab, a novel biologic DMARD, which has been approved for use in the treatment of certain patients with SLE.